ClinicalTrials.gg
RecruitingNCT07243626Updated Apr 24, 2026

Efficacy and Safety of Envafolimab Plus Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcoma

A Phase 2 interventional study of Envafolimab combined with an AI regimen (doxorubicin and ifosfamide) in Soft Tissue Sarcoma, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Sep 2024, registered Sep 2025).
  • Started Sep 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 133 studies in Sarcoma with a site in China — 68 open to participants now, 74 under way, 1 of them phase 3. Sarcoma · China.

Planned enrollment
90th of 122
25 · median 45
Started
2024
with 14 others
Phase 2
67 of 133
32 open now
Primary completion
2026-12
later than 34 of 73 live
Registered
111th of 133
by date
Lead sponsor
7 of 133
Second Affiliated Hospital, School of Medicine, Zhejiang University

Among the 133 studies in Sarcoma with a site in China, this one is the 90th largest by planned enrollment of the 122 interventional ones that give a count, is one of 15 that started in 2024, is one of 67 in phase 2, reaches primary completion later than 34 of the 73 other live ones, and was the 111th registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

68 of the 133 studies in Sarcoma with a site in China are open now. Recruiting first, the newest first:

62 more — sign in →

All 68 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 133 studies in Sarcoma with a site in China, or all of them as a file.
02

Study summary

Soft tissue sarcoma (STS) is a rare, highly heterogeneous malignancy with a poor prognosis. The standard first-line treatment for advanced patients is anthracyclines (doxorubicin, A) combined with ifosfamide (I, AI regimen), but the efficacy is limited, and some subtypes do not respond well. Immune checkpoint inhibitors (ICI) have shown potential in specific STS subtypes. Anthracyclines can induce immunogenic cell death and upregulate PD-L1, providing a theoretical basis for combined immunotherapy. Previous studies have shown that ICI combined with chemotherapy (such as pembrolizumab + doxorubicin) is more effective than chemotherapy alone. Envolizumab is the world's first subcutaneously injected PD-L1 single-domain antibody-Fc fusion protein, with significant advantages: (1) small molecular weight (\~80kDa) and strong tissue penetration; (2) high stability and can be stored at room temperature; (3) convenient subcutaneous injection and good tolerability (Phase II study of MSI-H/dMMR solid tumors ORR 42.7%, grade 3-4 TEAE 15.5%). In 2022, the FDA granted orphan drug designation for the treatment of STS.

This study aims to evaluate the efficacy (ORR, PFS, OS, etc.) and safety of Envolizumab combined with an AI regimen (doxorubicin + ifosfamide) as a first-line treatment for advanced STS.

Read the detailed description

Soft tissue sarcoma (STS) encompasses a diverse group of rare, high-grade malignancies originating from mesenchymal tissues, exhibiting significant heterogeneity in histology, molecular characteristics, and clinical behavior. The prognosis for advanced or metastatic STS remains generally poor, underscoring the urgent need for more effective therapeutic strategies. Currently, the standard first-line treatment for advanced STS involves chemotherapy regimens comprising anthracyclines, primarily doxorubicin, often combined with ifosfamide (the AI regimen). While these regimens can induce tumor responses, their overall efficacy is limited, with modest response rates and survival benefits. Moreover, certain STS subtypes demonstrate resistance to conventional chemotherapy, highlighting the necessity for novel and combination treatment approaches.

Recent advances in immunotherapy, particularly immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 pathways, have opened new avenues for treating specific STS subtypes. Evidence suggests that anthracyclines, such as doxorubicin, can induce immunogenic cell death, enhance tumor antigen presentation, and upregulate PD-L1 expression, creating a compelling rationale for combining chemotherapy with immunotherapy. Indeed, clinical studies have demonstrated that combining ICIs like pembrolizumab with chemotherapy regimens can improve objective response rates (ORR), progression-free survival (PFS), and overall survival (OS) compared to chemotherapy alone in certain patient populations.

Envolizumab represents a groundbreaking development in the realm of immunotherapeutics. As the world's first subcutaneously injectable PD-L1 single-domain antibody-Fc fusion protein, it boasts several distinct advantages: a small molecular weight (\~80 kDa) that ensures superior tissue penetration, high stability with room temperature storage capability, and a convenient subcutaneous administration route that enhances patient tolerability and adherence. Phase II clinical data have demonstrated promising anti-tumor activity in MSI-H/dMMR solid tumors, with an ORR of 42.7%, and an acceptable safety profile, with grade 3-4 treatment-emergent adverse events (TEAEs) in only 15.5% of patients. Notably, in 2022, the FDA granted orphan drug designation to Envolizumab for the treatment of STS, highlighting its potential as a novel therapeutic option.

This study aims to systematically evaluate the efficacy and safety of combining Envolizumab with the AI chemotherapy regimen as a first-line treatment for patients with advanced STS. The primary endpoint will focus on the overall response rate (ORR), with secondary endpoints including disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety profile assessments. The study hypothesizes that this combination could synergistically enhance anti-tumor immune responses, improve clinical outcomes, and offer a more tolerable treatment option for patients with advanced STS. The findings could potentially establish a new standard of care and provide critical insights into the integration of immunotherapy and chemotherapy in the management of this challenging malignancy.

03

Conditions studied

  • Soft Tissue Sarcoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed advanced soft tissue sarcoma with at least one .
  2. No previous systemic treatment.
  3. ≥18 years old; expected survival time more than 3 months;
  4. Major organ function within 7 days before treatment, meeting the following criteria:

(1) Routine blood test criteria (without blood transfusion within 14 days):

  • (HB) ≥90g/L; ② (ANC) ≥1.5×109/L; ③ count (PLT) ≥80×109/L. (2) Biochemical examinations must meet the following criteria: ① Total (TBIL) ≤ 1.5 times the (ULN); ② (ALT) and aspartate aminotransferase AST ≤ 2.5 ULN. If liver is present, ALT and AST ≤ 5 ULN; ③ Serum creatinine (Cr) ≤ 1.5 ULN or (CCr) ≥ 60ml/min; (3) Doppler ultrasound assessment: (LVEF) ≥ lower limit of normal (50%). 5. Women of childbearing age must agree to use measures (such as intrauterine devices, birth control pills or condoms) during the study and within 6 months after the study; serum or urine pregnancy tests must be negative within 7 days before study enrollment, and the patients must not be breastfeeding; men must agree to use contraceptive measures during the study and within 6 months after the study.

Exclusion criteria

Exclusion Criteria:

  1. Chondrosarcoma (CS), osteosarcoma (OS), Ewing's sarcoma, dermatofibrosarcoma protuberans (DFSP), and gastrointestinal stromal sarcoma (GIST) are excluded;
  2. Pregnant or lactating women, or women of who are not using measures;
  3. Current severe, uncontrolled acute infection; or purulent or chronic infection with a persistent wound;
  4. Presence of a second primary tumor (excluding basal cell carcinoma of the skin);
  5. Participation in other drug clinical trials within 4 weeks;
  6. Presence of severe heart disease, including congestive heart failure, uncontrolled high-risk arrhythmias, unstable angina, myocardial infarction, severe valvular heart disease, and hypertension;
  7. Suffering from uncontrolled neurological, psychiatric, or mental disorders, poor compliance, and inability to match the medication. Patients with uncontrolled primary brain tumors or central nervous system and significant intracranial hypertension or neuropsychiatric symptoms are excluded.
  8. Evidence of a hereditary bleeding diathesis or coagulopathy.
  9. A history of severe allergic/anaphylactic reactions to humanized antibodies.
  10. Diagnosed with immunodeficiency or receiving systemic or any other form of therapy within 14 days prior to the first dose of the study drug. Physiological doses of glucocorticoids (≤10 mg/day of prednisone or equivalent) are permitted.
  11. Subjects with active, known, or suspected diseases (e.g., interstitial pneumonitis, colitis, hepatitis, hypophysitis, vasculitis, nephritis, including but not limited to these diseases or syndromes) are excluded.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    intervention

    Eligible patients with soft tissue sarcoma were enrolled and treated with Envafolimab 300 mg/dose subcutaneously every 3 weeks on day 1. The AI regimen consisted of liposomal doxorubicin 35 mg/m² on day 1 and intravenous infusion of IFO 2.5 mg/m² on days 1-3, every 3 weeks. Efficacy and safety were assessed approximately every 6 weeks (42 ± 7 days). Patients with disease control (CR+PR+SD) and tolerable adverse reactions could choose continue treatment until disease progression, unacceptable toxicity, or discontinuation at the investigator's discretion.

    Drug: Envafolimab combined with an AI regimen (doxorubicin and ifosfamide)

Interventions

  • DrugEnvafolimab combined with an AI regimen (doxorubicin and ifosfamide)

    Envafolimab combined with an AI regimen: liposomal doxorubicin 35 mg/m² on day 1; IFO 2.5 mg/m² on days 1-3, intravenous infusion, every 3 weeks.

06

What researchers measure

Primary outcomes

  1. Efficcy-Progression-free survival

    PFS

    Time frame: From enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months

Secondary outcomes

  1. Efficcy-Objective response rate

    Objective response rate(ORR) =CR+PR

    Time frame: From enrollment to the end of treatment at 8 weeks

  2. Efficcy-Disease control rate

    DCR=CR+PR+SD

    Time frame: From enrollment to the end of treatment at 8 weeks

  3. Efficcy-overall survival

    OS

    Time frame: From enrollment until the date of death from any cause, assessed up to 60 months

  4. adverse events-safety

    adverse events

    Time frame: From enrollment to the end of treatment at 8 weeks

  5. Efficacy: 1-year os rate

    the estimated percentage of patients who remain alive

    Time frame: From enrollment to 1 year

07

Study locations

1 of 1 sites recruiting
  • Department of Medical Oncology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
    Hanzhong, Zhejiang 310009, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — only IPD used in the results publication

Supporting information: Study protocol

Time frame: 2025.8.3-2026-9.1

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Dec 2026, 27 months after the start.

Of 198 non-industry phase 2 interventional studies under Sarcoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 91. This study's planned 27 months is below that.

Counting every sponsor, half of 227 studies reached it within 66 months; a quarter within 43 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2025
First posted
Nov 24, 2025
StartActual
Sep 30, 2024
Primary completionEst.
Dec 30, 2026
CompletionEst.
Jun 1, 2027
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07243626
Responsible party
Sponsor
First posted
Nov 24, 2025
Start date
Sep 30, 2024
Primary completion
Dec 30, 2026 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Apr 24, 2026

Study contacts

Ying Dong
Contact
dongying74@zju.edu.cn
+8113666669105

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion